Cantillon Capital Management LLC reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,290,427 shares of the medical instruments supplier’s stock after selling 54,000 shares during the quarter. Becton, Dickinson and comprises approximately 3.1% of Cantillon Capital Management LLC’s portfolio, making the stock its 17th biggest holding. Cantillon Capital Management LLC owned approximately 0.60% of Becton, Dickinson and worth $251,775,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Janney Montgomery Scott LLC lifted its position in shares of Becton, Dickinson and by 35.3% in the second quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock valued at $8,447,000 after acquiring an additional 11,300 shares in the last quarter. Bessemer Group Inc. lifted its position in Becton, Dickinson and by 1.4% during the second quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock worth $190,827,000 after buying an additional 13,263 shares during the period. State of Alaska Department of Revenue lifted its position in Becton, Dickinson and by 5.8% during the second quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock worth $6,438,000 after buying an additional 1,819 shares during the period. Union Bankshares Corp lifted its position in Becton, Dickinson and by 1.7% during the second quarter. Union Bankshares Corp now owns 22,335 shares of the medical instruments supplier’s stock worth $4,357,000 after buying an additional 381 shares during the period. Finally, Retirement Systems of Alabama lifted its position in Becton, Dickinson and by 4.8% during the second quarter. Retirement Systems of Alabama now owns 161,834 shares of the medical instruments supplier’s stock worth $31,575,000 after buying an additional 7,358 shares during the period. Institutional investors and hedge funds own 87.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Cantillon Capital Management LLC Sells 54,000 Shares of Becton, Dickinson and Company (BDX)” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/09/23/cantillon-capital-management-llc-sells-54000-shares-of-becton-dickinson-and-company-bdx.html.

BDX has been the topic of several recent analyst reports. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Bank of America Corporation reiterated a “buy” rating and set a $225.00 target price (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research report on Monday, July 17th. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 target price on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $198.69.

In related news, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction on Friday, September 8th. The stock was sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the sale, the insider now owns 14,038 shares of the company’s stock, valued at $2,814,057.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares of the company’s stock, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,904 shares of company stock valued at $15,242,688. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (NYSE:BDX) opened at 193.06 on Friday. The stock has a market capitalization of $43.93 billion, a P/E ratio of 55.91 and a beta of 1.06. The stock has a 50 day moving average price of $199.01 and a 200-day moving average price of $191.58. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The business’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.35 earnings per share. Equities research analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a dividend of $0.73 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.51%. Becton, Dickinson and’s payout ratio is 83.43%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.